{
    "info": {
        "nct_id": "NCT06186401",
        "official_title": "Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma",
        "inclusion_criteria": "* Inclusion Criteria for Cohort 1:\n\n  1. Age >= 18 years.\n  2. Karnofsky performance status (KPS) score of >=70.\n  3. All participants must have adequate organ function defined as:\n\n     1. Peripheral absolute neutrophil count >=1000/mm^3.\n     2. Platelet count >=100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n     3. Absolute lymphocyte count (ALC) >= 300/μL and/or Cluster of differentiation 3 (CD3) count of >=150/μL.\n     4. Creatinine clearance or radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2.\n     5. Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome and\n     6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN).\n     7. Left ventricular ejection fraction (LVEF) >= 40% by echocardiogram or multi-gated acquisition scanning (MUGA).\n     8. Adequate pulmonary function, defined as no evidence of dyspnea at rest and pulse oximetry > 92% while breathing room air.\n  4. Pathological criteria: EGFRvIII+ GBM from most recent surgery, confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified lab using a next-generation sequencing panel.\n  5. MGMT promoter must be unmethylated or with a methylation index < 3.\n  6. Must have completed at least standard of care (SOC) external beam radiotherapy (EBRT) as initial therapy.\n  7. Participants must be anticipated to be able to complete E-SYNC T cell infusion within 12 weeks after completion of EBRT.\n  8. All participants must be off systemic steroids for 3 days or more prior to leukapheresis.\n  9. Must be willing to provide voluntary informed consent for apheresis (and tissue screening if needed) and for study treatment.\n\nNOTE: There are two sets of eligibility criteria for Cohort 2. Step 1 defines eligibility for tissue screening and apheresis, and Step 2 defines eligibility for study enrollment and E-SYNC T cell treatment.\n\n* Inclusion Criteria for Cohort 2, Step 1:\n\n  1. Age >=18 years.\n  2. KPS score >=70.\n  3. All participants must have adequate organ function defined as:\n\n     1. Peripheral absolute neutrophil count >=1000/mm^3.\n     2. Platelet count >=100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n     3. Absolute lymphocyte count (ALC) >= 300/μL and/or CD3 count of >=150/μL.\n     4. Creatinine clearance or radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2.\n     5. Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome and\n     6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN).\n     7. Left ventricular ejection fraction (LVEF) >= 40% by echocardiogram or multi-gated acquisition scanning (MUGA).\n     8. Adequate pulmonary function, defined as no evidence of dyspnea at rest and pulse oximetry > 92% while breathing room air.\n  4. Pathological criteria: EGFRvIII+ GBM from most recent surgery, as defined by an EGFRvIII + H-score of >=250 based on central review.\n  5. All participants must be off systemic steroids for 3 days or more prior to leukapheresis.\n  6. Must be willing to provide voluntary informed consent for apheresis (and tissue screening if needed).\n* Inclusion Criteria for Cohort 2, Step 2. Note: Prior to Step 2, participants must have undergone leukapheresis in Step 1. In addition:\n\n  1. KPS score >=70.\n  2. Must have received at least SOC EBRT as initial therapy; any number of prior recurrences is allowed.\n  3. Pathological criteria: EGFRvIII+ GBM from most recent surgery, as defined by an EGFRvIII + H-score of >=250 based on central review.\n  4. Must have radiographic progression consistent with the Response assessment in neuro-oncology criteria (RANO) criteria for progressive disease (PD)\n  5. Recurrence must be surgically amenable, with expectation for ability to resect at least 500mg of tumor tissue\n  6. Participants with reproductive potential agree to use reliable and double barrier method of contraception during the study and for at least 6 months after the last study intervention, including refraining from donating sperm during this period.\n  7. Females of childbearing potential must have a negative serum beta-Human Chorionic Gonadotropin (hCG) pregnancy test prior to receiving study interventions.\n  8. All participants must have adequate organ function defined as:\n\n     1. Peripheral absolute neutrophil count >=1000/mm^3.\n     2. Platelet count >=100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n     3. Absolute lymphocyte count (ALC) >= 300/μL and/or CD3 count of >=150/μL.\n     4. Creatinine clearance or radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2.\n     5. Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome and\n     6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN).\n     7. Coagulation tests prothrombin time (PT) and partial thromboplastin time (PTT) have to be within normal limits, unless the participant has been therapeutically anticoagulated for previous venous thrombosis.\n     8. Adequate pulmonary function, defined as no evidence of dyspnea at rest and pulse oximetry > 92% while breathing room air.\n     9. Adequate cardiac function, confirmed within the last 12 months, defined as left ventricular ejection fraction (LVEF) >= 40% by echocardiogram or multi-gated acquisition scanning (MUGA).\n  9. Must be willing to provide voluntary informed consent for apheresis (and tissue screening if needed).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Exclusion Criteria for Cohort 1\n\n  1. Participant who has been treated with any investigational agents and chemotherapy targeting GBM <= 4 weeks prior to date of study registration. Exceptions to this include: must be >=23 days from last dose of temozolomide (TMZ) or radiotherapy, mush be >= 6 weeks from last dose of nitrosourea.\n  2. Female participants of reproductive potential who are pregnant or lactating. Female study participants of reproductive potential must have a negative serum pregnancy test as part of eligibility confirmation.\n  3. Known addiction to alcohol or illicit drugs.\n  4. Prior treatment with any Epithelial Growth Factor Receptor (EGFR)-targeting therapy.\n  5. Participants with leptomeningeal dissemination.\n  6. Participants with a known disorder that affects their immune system, such as human immunodeficiency virus (HIV) or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy. Participants who are currently using non-systemic steroids (e.g., inhaled, intranasal, ocular, topical) are not excluded from the study.\n  7. Participants with serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B surface antigen (HBsAg+) will be excluded. Participants that are positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. PCR positive participants will be excluded.\n  8. Participants who have received prior solid organ or bone marrow transplantation.\n  9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, second cancer currently receiving active treatment or anticipated to receive treatment within the next year, or psychiatric illness/social situations that would limit compliance with study requirements.\n  10. Participants who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.\n* Exclusion Criteria for Step 1 for Cohort 2\n\n  1. Participant who has been treated with any investigational agents or chemotherapy targeting GBM <=4 weeks prior to date of study registration. Exceptions to this include: must be>= 23 days from last dose of TMZ or radiotherapy, must be>=6 weeks from last dose of nitrosourea.\n  2. Female participants of reproductive potential who are pregnant or lactating. Female study participants of reproductive potential must have a negative serum pregnancy test as part of Step 1 eligibility confirmation.\n  3. Uncontrolled active infection.\n  4. Participants with a known disorder that affects their immune system, such as HIV or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy.\n\n     Participants who are currently using non-systemic steroids (e.g., inhaled, intranasal, ocular, topical) are not excluded from the study.\n  5. Participants with serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B surface antigen (HBsAg+) will be excluded. Participants that are positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. PCR positive participants will be excluded.\n  6. Known addiction to alcohol or illicit drugs.\n* Exclusion Criteria for Step 2 for Cohort 2\n\nPrior to Step 2, participants must have undergone leukapheresis in Step 1. In addition:\n\n1. Prior treatment with any EGFR-targeting therapy\n2. Participant who has been treated with any investigational agents or chemotherapy targeting GBM <= 4 weeks prior to date of study registration. Exceptions to this include: must be >= 23 days from last dose of TMZ or radiotherapy, must be >= 6 weeks from last dose of nitrosourea.\n3. Participants with imaging or clinical evidence of uncontrolled tumor mass effect; the assessment of mass effect will be made by the Investigators.\n4. Participants with leptomeningeal dissemination.\n5. Participants with a known disorder that affects their immune system, such as HIV or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy.\n\n   Participants who are currently using inhaled, intranasal, ocular, topical, or other non-oral or non-IV steroids are not necessarily excluded from the study.\n6. Participants with serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B surface antigen (HBsAg+) will be excluded. Participants that are positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. PCR positive participants will be excluded.\n7. Participants who have received prior solid organ or bone marrow transplantation.\n8. Female participants who are pregnant or breast-feeding.\n9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, second cancer currently receiving active treatment or anticipated to receive treatment within the next year, or psychiatric illness/social situations that would limit compliance with study requirements.\n10. Participants who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "3. All participants must have adequate organ function defined as:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. All participants must have adequate organ function defined as:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate pulmonary function, defined as no evidence of dyspnea at rest and pulse oximetry > 92% while breathing room air.",
            "criterions": [
                {
                    "exact_snippets": "no evidence of dyspnea at rest",
                    "criterion": "dyspnea at rest",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "pulse oximetry > 92% while breathing room air",
                    "criterion": "pulse oximetry while breathing room air",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Absolute lymphocyte count (ALC) >= 300/μL and/or Cluster of differentiation 3 (CD3) count of >=150/μL.",
            "criterions": [
                {
                    "exact_snippets": "Absolute lymphocyte count (ALC) >= 300/μL",
                    "criterion": "absolute lymphocyte count (ALC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 300,
                                "unit": "μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Cluster of differentiation 3 (CD3) count of >=150/μL",
                    "criterion": "Cluster of differentiation 3 (CD3) count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate pulmonary function, defined as no evidence of dyspnea at rest and pulse oximetry > 92% while breathing room air.",
            "criterions": [
                {
                    "exact_snippets": "no evidence of dyspnea at rest",
                    "criterion": "dyspnea at rest",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "pulse oximetry > 92% while breathing room air",
                    "criterion": "pulse oximetry",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Left ventricular ejection fraction (LVEF) >= 40% by echocardiogram or multi-gated acquisition scanning (MUGA).",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >= 40%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "echocardiogram",
                                "multi-gated acquisition scanning (MUGA)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Must have completed at least standard of care (SOC) external beam radiotherapy (EBRT) as initial therapy.",
            "criterions": [
                {
                    "exact_snippets": "Must have completed at least standard of care (SOC) external beam radiotherapy (EBRT) as initial therapy.",
                    "criterion": "external beam radiotherapy (EBRT) as initial therapy",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "minimum standard",
                            "expected_value": "standard of care (SOC)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Absolute lymphocyte count (ALC) >= 300/μL and/or CD3 count of >=150/μL.",
            "criterions": [
                {
                    "exact_snippets": "Absolute lymphocyte count (ALC) >= 300/μL",
                    "criterion": "absolute lymphocyte count (ALC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 300,
                                "unit": "μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CD3 count of >=150/μL",
                    "criterion": "CD3 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Absolute lymphocyte count (ALC) >= 300/μL and/or CD3 count of >=150/μL.",
            "criterions": [
                {
                    "exact_snippets": "Absolute lymphocyte count (ALC) >= 300/μL",
                    "criterion": "absolute lymphocyte count (ALC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 300,
                                "unit": "μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CD3 count of >=150/μL",
                    "criterion": "CD3 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Peripheral absolute neutrophil count >=1000/mm^3.",
            "criterions": [
                {
                    "exact_snippets": "Peripheral absolute neutrophil count >=1000/mm^3",
                    "criterion": "peripheral absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Coagulation tests prothrombin time (PT) and partial thromboplastin time (PTT) have to be within normal limits, unless the participant has been therapeutically anticoagulated for previous venous thrombosis.",
            "criterions": [
                {
                    "exact_snippets": "Coagulation tests prothrombin time (PT) ... have to be within normal limits",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "Coagulation tests ... partial thromboplastin time (PTT) have to be within normal limits",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the participant has been therapeutically anticoagulated for previous venous thrombosis",
                    "criterion": "therapeutic anticoagulation for previous venous thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Pathological criteria: EGFRvIII+ GBM from most recent surgery, confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified lab using a next-generation sequencing panel.",
            "criterions": [
                {
                    "exact_snippets": "EGFRvIII+ GBM from most recent surgery",
                    "criterion": "glioblastoma multiforme (GBM)",
                    "requirements": [
                        {
                            "requirement_type": "EGFRvIII mutation status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "most recent surgery"
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified lab using a next-generation sequencing panel",
                    "criterion": "EGFRvIII+ GBM diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "next-generation sequencing panel"
                        },
                        {
                            "requirement_type": "laboratory certification",
                            "expected_value": "CLIA-certified"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Must have radiographic progression consistent with the Response assessment in neuro-oncology criteria (RANO) criteria for progressive disease (PD)",
            "criterions": [
                {
                    "exact_snippets": "Must have radiographic progression consistent with the Response assessment in neuro-oncology criteria (RANO) criteria for progressive disease (PD)",
                    "criterion": "radiographic progression (per RANO criteria)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consistency with RANO criteria for progressive disease",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Pathological criteria: EGFRvIII+ GBM from most recent surgery, as defined by an EGFRvIII + H-score of >=250 based on central review.",
            "criterions": [
                {
                    "exact_snippets": "EGFRvIII+ GBM from most recent surgery",
                    "criterion": "GBM EGFRvIII status",
                    "requirements": [
                        {
                            "requirement_type": "EGFRvIII positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "EGFRvIII + H-score of >=250 based on central review",
                    "criterion": "EGFRvIII H-score",
                    "requirements": [
                        {
                            "requirement_type": "H-score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 250,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Creatinine clearance or radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ... >= 50 mL/min/1.73m^2",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min/1.73m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2",
                    "criterion": "radioisotope glomerular filtration rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min/1.73m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate pulmonary function, defined as no evidence of dyspnea at rest and pulse oximetry > 92% while breathing room air.",
            "criterions": [
                {
                    "exact_snippets": "no evidence of dyspnea at rest",
                    "criterion": "dyspnea at rest",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "pulse oximetry > 92% while breathing room air",
                    "criterion": "pulse oximetry",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Left ventricular ejection fraction (LVEF) >= 40% by echocardiogram or multi-gated acquisition scanning (MUGA).",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >= 40%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "by echocardiogram or multi-gated acquisition scanning (MUGA)",
                    "criterion": "LVEF measurement method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "echocardiogram",
                                "multi-gated acquisition scanning (MUGA)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Peripheral absolute neutrophil count >=1000/mm^3.",
            "criterions": [
                {
                    "exact_snippets": "Peripheral absolute neutrophil count >=1000/mm^3.",
                    "criterion": "peripheral absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. KPS score >=70.",
            "criterions": [
                {
                    "exact_snippets": "KPS score >=70",
                    "criterion": "Karnofsky Performance Status (KPS) score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome and",
            "criterions": [
                {
                    "exact_snippets": "Total Bilirubin <= 1.5 x ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for Gilbert's syndrome",
                    "criterion": "Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Pathological criteria: EGFRvIII+ GBM from most recent surgery, as defined by an EGFRvIII + H-score of >=250 based on central review.",
            "criterions": [
                {
                    "exact_snippets": "EGFRvIII+ GBM from most recent surgery",
                    "criterion": "GBM EGFRvIII status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "EGFRvIII positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "EGFRvIII + H-score of >=250 based on central review",
                    "criterion": "EGFRvIII H-score",
                    "requirements": [
                        {
                            "requirement_type": "H-score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 250,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "central review"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Creatinine clearance or radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ... >= 50 mL/min/1.73m^2",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min/1.73m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2",
                    "criterion": "radioisotope glomerular filtration rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min/1.73m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelet count >=100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >=100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "independence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "no transfusion duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. All participants must be off systemic steroids for 3 days or more prior to leukapheresis.",
            "criterions": [
                {
                    "exact_snippets": "off systemic steroids for 3 days or more prior to leukapheresis",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "absence_duration_before_leukapheresis",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Recurrence must be surgically amenable, with expectation for ability to resect at least 500mg of tumor tissue",
            "criterions": [
                {
                    "exact_snippets": "Recurrence must be surgically amenable",
                    "criterion": "recurrence",
                    "requirements": [
                        {
                            "requirement_type": "surgical amenability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "expectation for ability to resect at least 500mg of tumor tissue",
                    "criterion": "tumor tissue resection",
                    "requirements": [
                        {
                            "requirement_type": "amount resectable",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "mg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Creatinine clearance or radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ... >= 50 mL/min/1.73m^2",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min/1.73m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radioisotope glomerular filtration rate >= 50 mL/min/1.73m^2",
                    "criterion": "radioisotope glomerular filtration rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min/1.73m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Peripheral absolute neutrophil count >=1000/mm^3.",
            "criterions": [
                {
                    "exact_snippets": "Peripheral absolute neutrophil count >=1000/mm^3",
                    "criterion": "peripheral absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Participants with reproductive potential agree to use reliable and double barrier method of contraception during the study and for at least 6 months after the last study intervention, including refraining from donating sperm during this period.",
            "criterions": [
                {
                    "exact_snippets": "Participants with reproductive potential",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to use reliable and double barrier method of contraception during the study and for at least 6 months after the last study intervention",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "reliable",
                                "double barrier"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "refraining from donating sperm during this period",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Adequate cardiac function, confirmed within the last 12 months, defined as left ventricular ejection fraction (LVEF) >= 40% by echocardiogram or multi-gated acquisition scanning (MUGA).",
            "criterions": [
                {
                    "exact_snippets": "Adequate cardiac function, confirmed within the last 12 months, defined as left ventricular ejection fraction (LVEF) >= 40% by echocardiogram or multi-gated acquisition scanning (MUGA)",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "left ventricular ejection fraction (LVEF)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. KPS score >=70.",
            "criterions": [
                {
                    "exact_snippets": "KPS score >=70",
                    "criterion": "Karnofsky Performance Status (KPS) score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Participants must be anticipated to be able to complete E-SYNC T cell infusion within 12 weeks after completion of EBRT.",
            "criterions": [
                {
                    "exact_snippets": "Participants must be anticipated to be able to complete E-SYNC T cell infusion within 12 weeks after completion of EBRT.",
                    "criterion": "E-SYNC T cell infusion",
                    "requirements": [
                        {
                            "requirement_type": "completion_time_after_EBRT",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inclusion Criteria for Cohort 2, Step 2. Note: Prior to Step 2, participants must have undergone leukapheresis in Step 1. In addition:",
            "criterions": [
                {
                    "exact_snippets": "Prior to Step 2, participants must have undergone leukapheresis in Step 1.",
                    "criterion": "leukapheresis in Step 1",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome and",
            "criterions": [
                {
                    "exact_snippets": "Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "NOTE: There are two sets of eligibility criteria for Cohort 2. Step 1 defines eligibility for tissue screening and apheresis, and Step 2 defines eligibility for study enrollment and E-SYNC T cell treatment.",
            "criterions": [
                {
                    "exact_snippets": "two sets of eligibility criteria for Cohort 2",
                    "criterion": "eligibility criteria sets for Cohort 2",
                    "requirements": [
                        {
                            "requirement_type": "number of sets",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "sets"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Step 1 defines eligibility for tissue screening and apheresis",
                    "criterion": "eligibility for tissue screening",
                    "requirements": [
                        {
                            "requirement_type": "step",
                            "expected_value": "Step 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Step 1 defines eligibility for tissue screening and apheresis",
                    "criterion": "eligibility for apheresis",
                    "requirements": [
                        {
                            "requirement_type": "step",
                            "expected_value": "Step 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Step 2 defines eligibility for study enrollment and E-SYNC T cell treatment",
                    "criterion": "eligibility for study enrollment",
                    "requirements": [
                        {
                            "requirement_type": "step",
                            "expected_value": "Step 2"
                        }
                    ]
                },
                {
                    "exact_snippets": "Step 2 defines eligibility for study enrollment and E-SYNC T cell treatment",
                    "criterion": "eligibility for E-SYNC T cell treatment",
                    "requirements": [
                        {
                            "requirement_type": "step",
                            "expected_value": "Step 2"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age >=18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age >=18 years.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Must be willing to provide voluntary informed consent for apheresis (and tissue screening if needed).",
            "criterions": [
                {
                    "exact_snippets": "willing to provide voluntary informed consent for apheresis",
                    "criterion": "informed consent for apheresis",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to provide voluntary informed consent for ... tissue screening if needed",
                    "criterion": "informed consent for tissue screening",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. MGMT promoter must be unmethylated or with a methylation index < 3.",
            "criterions": [
                {
                    "exact_snippets": "MGMT promoter must be unmethylated",
                    "criterion": "MGMT promoter methylation status",
                    "requirements": [
                        {
                            "requirement_type": "methylation status",
                            "expected_value": "unmethylated"
                        }
                    ]
                },
                {
                    "exact_snippets": "MGMT promoter ... with a methylation index < 3",
                    "criterion": "MGMT promoter methylation index",
                    "requirements": [
                        {
                            "requirement_type": "methylation index",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelet count >=100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >=100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence of transfusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age >= 18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Must have received at least SOC EBRT as initial therapy; any number of prior recurrences is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Must have received at least SOC EBRT as initial therapy",
                    "criterion": "initial therapy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "SOC EBRT"
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any number of prior recurrences is allowed",
                    "criterion": "prior recurrences",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "any number allowed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelet count >=100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >=100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment",
                    "criterion": "platelet transfusion independence",
                    "requirements": [
                        {
                            "requirement_type": "absence of platelet transfusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Karnofsky performance status (KPS) score of >=70.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance status (KPS) score of >=70",
                    "criterion": "Karnofsky performance status (KPS) score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Must be willing to provide voluntary informed consent for apheresis (and tissue screening if needed) and for study treatment.",
            "criterions": [
                {
                    "exact_snippets": "willing to provide voluntary informed consent for apheresis",
                    "criterion": "informed consent for apheresis",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to provide voluntary informed consent for ... tissue screening if needed",
                    "criterion": "informed consent for tissue screening",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to provide voluntary informed consent ... for study treatment",
                    "criterion": "informed consent for study treatment",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. All participants must have adequate organ function defined as:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome and",
            "criterions": [
                {
                    "exact_snippets": "Total Bilirubin <= 1.5 x ULN except for Gilbert's syndrome",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Must be willing to provide voluntary informed consent for apheresis (and tissue screening if needed).",
            "criterions": [
                {
                    "exact_snippets": "willing to provide voluntary informed consent for apheresis",
                    "criterion": "informed consent for apheresis",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "voluntariness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to provide voluntary informed consent for ... tissue screening if needed",
                    "criterion": "informed consent for tissue screening",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "voluntariness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Females of childbearing potential must have a negative serum beta-Human Chorionic Gonadotropin (hCG) pregnancy test prior to receiving study interventions.",
            "criterions": [
                {
                    "exact_snippets": "Females of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum beta-Human Chorionic Gonadotropin (hCG) pregnancy test prior to receiving study interventions",
                    "criterion": "serum beta-Human Chorionic Gonadotropin (hCG) pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to receiving study interventions"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. All participants must be off systemic steroids for 3 days or more prior to leukapheresis.",
            "criterions": [
                {
                    "exact_snippets": "off systemic steroids for 3 days or more prior to leukapheresis",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "absence duration prior to leukapheresis",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "5. Participants with a known disorder that affects their immune system, such as HIV or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy.",
            "criterions": [
                {
                    "exact_snippets": "known disorder that affects their immune system",
                    "criterion": "immune system disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "such as HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy",
                    "criterion": "autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic cytotoxic or immunosuppressive therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Prior to Step 2, participants must have undergone leukapheresis in Step 1. In addition:",
            "criterions": [
                {
                    "exact_snippets": "participants must have undergone leukapheresis in Step 1",
                    "criterion": "leukapheresis in Step 1",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participants with serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B surface antigen (HBsAg+) will be excluded. Participants that are positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. PCR positive participants will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "serologic status reflecting active hepatitis B or C infection",
                    "criterion": "active hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis B surface antigen (HBsAg+) will be excluded",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment",
                    "criterion": "hepatitis B core antibody or hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative polymerase chain reaction (PCR) prior to enrollment",
                    "criterion": "hepatitis B or C PCR",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "PCR positive participants will be excluded",
                    "criterion": "hepatitis B or C PCR",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participants with leptomeningeal dissemination.",
            "criterions": [
                {
                    "exact_snippets": "Participants with leptomeningeal dissemination.",
                    "criterion": "leptomeningeal dissemination",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Known addiction to alcohol or illicit drugs.",
            "criterions": [
                {
                    "exact_snippets": "Known addiction to alcohol",
                    "criterion": "alcohol addiction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known addiction to ... illicit drugs",
                    "criterion": "illicit drug addiction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Participants with a known disorder that affects their immune system, such as human immunodeficiency virus (HIV) or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy. Participants who are currently using non-systemic steroids (e.g., inhaled, intranasal, ocular, topical) are not excluded from the study.",
            "criterions": [
                {
                    "exact_snippets": "Participants with a known disorder that affects their immune system, such as human immunodeficiency virus (HIV) or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy.",
                    "criterion": "disorder affecting immune system",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "human immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy",
                    "criterion": "autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants who are currently using inhaled, intranasal, ocular, topical, or other non-oral or non-IV steroids are not necessarily excluded from the study.",
            "criterions": [
                {
                    "exact_snippets": "currently using inhaled, intranasal, ocular, topical, or other non-oral or non-IV steroids",
                    "criterion": "use of non-oral or non-IV steroids",
                    "requirements": [
                        {
                            "requirement_type": "route of administration",
                            "expected_value": [
                                "inhaled",
                                "intranasal",
                                "ocular",
                                "topical",
                                "other non-oral",
                                "non-IV"
                            ]
                        },
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participant who has been treated with any investigational agents or chemotherapy targeting GBM <=4 weeks prior to date of study registration. Exceptions to this include: must be>= 23 days from last dose of TMZ or radiotherapy, must be>=6 weeks from last dose of nitrosourea.",
            "criterions": [
                {
                    "exact_snippets": "treated with any investigational agents or chemotherapy targeting GBM <=4 weeks prior to date of study registration",
                    "criterion": "treatment with investigational agents or chemotherapy targeting GBM",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be>= 23 days from last dose of TMZ",
                    "criterion": "time since last dose of TMZ",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be>= 23 days from last dose of ... radiotherapy",
                    "criterion": "time since last dose of radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be>=6 weeks from last dose of nitrosourea",
                    "criterion": "time since last dose of nitrosourea",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Known addiction to alcohol or illicit drugs.",
            "criterions": [
                {
                    "exact_snippets": "Known addiction to alcohol",
                    "criterion": "alcohol addiction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known addiction to ... illicit drugs",
                    "criterion": "illicit drug addiction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Participants who have received prior solid organ or bone marrow transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Participants who have received prior solid organ or bone marrow transplantation",
                    "criterion": "prior transplantation",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "solid organ",
                                "bone marrow"
                            ]
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Participants with leptomeningeal dissemination.",
            "criterions": [
                {
                    "exact_snippets": "Participants with leptomeningeal dissemination",
                    "criterion": "leptomeningeal dissemination",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Female participants who are pregnant or breast-feeding.",
            "criterions": [
                {
                    "exact_snippets": "Female participants who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Female participants who are ... breast-feeding",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "breast-feeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participants with a known disorder that affects their immune system, such as HIV or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy.",
            "criterions": [
                {
                    "exact_snippets": "known disorder that affects their immune system",
                    "criterion": "immune system disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "such as HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy",
                    "criterion": "autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants who are currently using non-systemic steroids (e.g., inhaled, intranasal, ocular, topical) are not excluded from the study.",
            "criterions": [
                {
                    "exact_snippets": "currently using non-systemic steroids (e.g., inhaled, intranasal, ocular, topical)",
                    "criterion": "non-systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Participants who have received prior solid organ or bone marrow transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Participants who have received prior solid organ or bone marrow transplantation",
                    "criterion": "prior transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history of solid organ transplantation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history of bone marrow transplantation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Female participants of reproductive potential who are pregnant or lactating. Female study participants of reproductive potential must have a negative serum pregnancy test as part of eligibility confirmation.",
            "criterions": [
                {
                    "exact_snippets": "Female participants of reproductive potential who are pregnant or lactating",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Female participants of reproductive potential who are pregnant or lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Female study participants of reproductive potential must have a negative serum pregnancy test as part of eligibility confirmation",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, second cancer currently receiving active treatment or anticipated to receive treatment within the next year, or psychiatric illness/social situations that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "second cancer currently receiving active treatment or anticipated to receive treatment within the next year",
                    "criterion": "second cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "currently receiving active treatment"
                        },
                        {
                            "requirement_type": "anticipated treatment",
                            "expected_value": "anticipated to receive treatment within the next year"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Prior treatment with any Epithelial Growth Factor Receptor (EGFR)-targeting therapy.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with any Epithelial Growth Factor Receptor (EGFR)-targeting therapy.",
                    "criterion": "prior EGFR-targeting therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Uncontrolled active infection.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled active infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, second cancer currently receiving active treatment or anticipated to receive treatment within the next year, or psychiatric illness/social situations that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "second cancer currently receiving active treatment or anticipated to receive treatment within the next year",
                    "criterion": "second cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": [
                                "currently receiving active treatment",
                                "anticipated to receive treatment within the next year"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participants with imaging or clinical evidence of uncontrolled tumor mass effect; the assessment of mass effect will be made by the Investigators.",
            "criterions": [
                {
                    "exact_snippets": "imaging or clinical evidence of uncontrolled tumor mass effect",
                    "criterion": "tumor mass effect",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "evidence",
                            "expected_value": [
                                "imaging",
                                "clinical"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "the assessment of mass effect will be made by the Investigators",
                    "criterion": "mass effect assessment",
                    "requirements": [
                        {
                            "requirement_type": "assessor",
                            "expected_value": "Investigators"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior treatment with any EGFR-targeting therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with any EGFR-targeting therapy",
                    "criterion": "prior treatment with EGFR-targeting therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participant who has been treated with any investigational agents or chemotherapy targeting GBM <= 4 weeks prior to date of study registration. Exceptions to this include: must be >= 23 days from last dose of TMZ or radiotherapy, must be >= 6 weeks from last dose of nitrosourea.",
            "criterions": [
                {
                    "exact_snippets": "treated with any investigational agents or chemotherapy targeting GBM <= 4 weeks prior to date of study registration",
                    "criterion": "prior treatment with investigational agents or chemotherapy targeting GBM",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be >= 23 days from last dose of TMZ or radiotherapy",
                    "criterion": "time since last dose of TMZ or radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be >= 6 weeks from last dose of nitrosourea",
                    "criterion": "time since last dose of nitrosourea",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Participants with serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B surface antigen (HBsAg+) will be excluded. Participants that are positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. PCR positive participants will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "serologic status reflecting active hepatitis B or C infection",
                    "criterion": "active hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis B surface antigen (HBsAg+) will be excluded",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. PCR positive participants will be excluded",
                    "criterion": "hepatitis B core antibody or hepatitis C antibody with PCR",
                    "requirements": [
                        {
                            "requirement_type": "antibody_presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "PCR_result",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Participants with serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B surface antigen (HBsAg+) will be excluded. Participants that are positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. PCR positive participants will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "serologic status reflecting active hepatitis B or C infection",
                    "criterion": "active hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis B surface antigen (HBsAg+) will be excluded",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis B core antibody or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment",
                    "criterion": "hepatitis B core antibody or hepatitis C antibody with PCR",
                    "requirements": [
                        {
                            "requirement_type": "antibody_presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "PCR_result",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "PCR positive participants will be excluded",
                    "criterion": "PCR for hepatitis B or C",
                    "requirements": [
                        {
                            "requirement_type": "PCR_result",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Participants who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.",
            "criterions": [
                {
                    "exact_snippets": "Participants who are unable to return for follow-up visits",
                    "criterion": "ability to return for follow-up visits",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to ... obtain follow-up studies required to assess toxicity to therapy",
                    "criterion": "ability to obtain follow-up studies required to assess toxicity to therapy",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Female participants of reproductive potential who are pregnant or lactating. Female study participants of reproductive potential must have a negative serum pregnancy test as part of Step 1 eligibility confirmation.",
            "criterions": [
                {
                    "exact_snippets": "Female participants of reproductive potential who are pregnant or lactating",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Female participants of reproductive potential who are pregnant or lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Female study participants of reproductive potential must have a negative serum pregnancy test as part of Step 1 eligibility confirmation",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Participants who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.",
            "criterions": [
                {
                    "exact_snippets": "Participants who are unable to return for follow-up visits",
                    "criterion": "ability to return for follow-up visits",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unable to ... obtain follow-up studies required to assess toxicity to therapy",
                    "criterion": "ability to obtain follow-up studies required to assess toxicity to therapy",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Inclusion Criteria for Cohort 1:",
            "criterions": []
        },
        {
            "line": "6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN).",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) <= 3x upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN).",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) <= 3x upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inclusion Criteria for Cohort 2, Step 1:",
            "criterions": []
        },
        {
            "line": "6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN).",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) <= 3x upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) <= 3x upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "1. Participant who has been treated with any investigational agents and chemotherapy targeting GBM <= 4 weeks prior to date of study registration. Exceptions to this include: must be >=23 days from last dose of temozolomide (TMZ) or radiotherapy, mush be >= 6 weeks from last dose of nitrosourea.",
            "criterions": [
                {
                    "exact_snippets": "treated with any investigational agents and chemotherapy targeting GBM <= 4 weeks prior to date of study registration",
                    "criterion": "treatment with investigational agents and chemotherapy targeting GBM",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be >=23 days from last dose of temozolomide (TMZ)",
                    "criterion": "time since last dose of temozolomide (TMZ)",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be >=23 days from last dose of ... radiotherapy",
                    "criterion": "time since last dose of radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 23,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be >= 6 weeks from last dose of nitrosourea",
                    "criterion": "time since last dose of nitrosourea",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exclusion Criteria for Step 2 for Cohort 2",
            "criterions": []
        },
        {
            "line": "* Exclusion Criteria for Cohort 1",
            "criterions": []
        },
        {
            "line": "* Exclusion Criteria for Step 1 for Cohort 2",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}